HOW TO BEST USE IMMUNE CHECKPOINT INHIBITORS IN NSCLC: SINGLE AGENTS OR COMBINED WITH CHEMOTHERAPY?

ROOM A
PALEXPOL, GENEVA, SWITZERLAND

Chair
David Planchard, France

WEDNESDAY, 10 APRIL 2019
11:45 - 13:15

11:45 Introduction
David Planchard, Villejuif, France

11:50 First-line immunotherapy options for patients without an oncogene driver
Raffaele Califano, Manchester, UK

12:10 What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors?
Marina Garassino, Milan, Italy

12:30 Are immune checkpoints (ICPs) better as single agent, doublet ICPs or combined with chemo +/- anti-angiogenics?
Solange Peters, Lausanne, Switzerland

12:50 Recommendation on second-line treatment according to first-line choice
David Planchard, Villejuif, France

13:10 Conclusion
David Planchard, Villejuif, France

This educational activity is provided by ESMO and supported by Lilly Oncology in collaboration with MSD.